REVANCE THERAPEUTICS INC (RVNC)

US7613301099 - Common Stock

4.08  +0.27 (+7.09%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

REVANCE THERAPEUTICS INC

NASDAQ:RVNC (7/16/2024, 11:09:02 AM)

4.08

+0.27 (+7.09%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-32.69%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap426.16M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

RVNC Daily chart

Company Profile

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The company is headquartered in Nashville, Tennessee and currently employs 534 full-time employees. The company went IPO on 2014-02-06. The firm is focused on advanced aesthetic and therapeutic offerings. The Company’s aesthetics portfolio of expertly created products and services, including DAXXIFY (DaxibotulinumtoxinA-lanm) for injection, the RHA Collection of dermal fillers, and OPUL, the first-of-its-kind relational commerce platform for aesthetic practices. The Company’s therapeutics pipeline is focused on muscle movement disorders, including evaluating DAXXIFY in two debilitating conditions, cervical dystonia and upper limb spasticity. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient along with the other excipients. DAXXIFY a commercially approved product, is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

Company Info

REVANCE THERAPEUTICS INC

1222 Demonbreun Street, Suite 2000

Nashville TENNESSEE 37203

P: 16157247755

CEO: Mark J. Foley

Employees: 534

Website: https://www.revance.com/

RVNC News

News Image5 days ago - InvestorPlaceStocks to Buy: 3 Breakout Stars to Transform Your Portfolio

Although breakout stocks present high risks, the underlying lack of predictability provides fuel for tremendous upside.

News Imagea month ago - Revance Therapeutics, Inc.Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Imagea month ago - Market News VideoInvestors Bag RVNC 53.9% Cheaper Than Its Secondary Stock Offering
News Image2 months ago - Revance Therapeutics, Inc.Revance to Participate in Upcoming Investor Conferences
News Image2 months ago - InvestorPlaceThe 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains

Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.

News Image2 months ago - InvestorPlace3 Underappreciated Stocks That Could 10x in 10 Years

10x stocks are the holy grail of capital investing. So, here are three companies that have the potential to cross that line.

RVNC Twits

Here you can normally see the latest stock twits on RVNC, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example